Business Description
Aligos Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US01626L2043
Share Class Description:
ALGS: Ordinary SharesTotal Employee Number:
82Description
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 12.61 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -17.5 | |||||
Beneish M-Score | -2.42 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -69.9 | |||||
3-Year EBITDA Growth Rate | 46.1 | |||||
3-Year EPS without NRI Growth Rate | 49.5 | |||||
3-Year FCF Growth Rate | 43.7 | |||||
3-Year Book Growth Rate | -47.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 135.78 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 74.97 | |||||
9-Day RSI | 70.93 | |||||
14-Day RSI | 65.13 | |||||
3-1 Month Momentum % | -35.46 | |||||
6-1 Month Momentum % | -42.67 | |||||
12-1 Month Momentum % | -41.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.56 | |||||
Quick Ratio | 2.56 | |||||
Cash Ratio | 2.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -53.2 | |||||
Shareholder Yield % | 8.41 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2033.39 | |||||
Net Margin % | -1919.68 | |||||
EBITDA Margin % | -1966.44 | |||||
FCF Margin % | -1810.52 | |||||
OCF Margin % | -1800.68 | |||||
ROE % | -120.27 | |||||
ROA % | -82.37 | |||||
ROIC % | -639.73 | |||||
3-Year ROIIC % | -63.95 | |||||
ROC (Joel Greenblatt) % | -1725.29 | |||||
ROCE % | -108.1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 14.65 | |||||
PB Ratio | 1.29 | |||||
Price-to-Tangible-Book | 1.29 | |||||
EV-to-EBIT | 0.1 | |||||
EV-to-EBITDA | 0.1 | |||||
EV-to-Revenue | -2.04 | |||||
EV-to-Forward-Revenue | 0.02 | |||||
EV-to-FCF | 0.11 | |||||
Price-to-GF-Value | 2.38 | |||||
| Price-to-Net-Current-Asset-Value | 1.53 | |||||
| Price-to-Net-Cash | 1.85 | |||||
Earnings Yield (Greenblatt) % | 1000 | |||||
FCF Yield % | -207.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALGS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aligos Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4.705 | ||
| EPS (TTM) ($) | -8.69 | ||
| Beta | 2.316 | ||
| 3-Year Sharpe Ratio | 0.08 | ||
| 3-Year Sortino Ratio | 0.16 | ||
| Volatility % | 60.5 | ||
| 14-Day RSI | 65.13 | ||
| 14-Day ATR ($) | 0.501751 | ||
| 20-Day SMA ($) | 5.67925 | ||
| 12-1 Month Momentum % | -41.3 | ||
| 52-Week Range ($) | 4.8 - 13.6892 | ||
| Shares Outstanding (Mil) | 6.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aligos Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aligos Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 118 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 26 days | ||
| General meeting for 2026 | 2026-06-25 08:00 | 5.58 (+0.63%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 6.37 (+0.95%) | ||
| Annual report for 2025 | 2026-03-05 | 6.86 (+1.63%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 6.86 (+1.63%) | ||
| Piper Sandler 37th Annual Healthcare Conference | 2025-12-03 14:00 | 9.21 (-1.50%) | ||
| Jefferies London Healthcare Conference | 2025-11-17 10:00 | 6.66 (+13.27%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 7.33 (+1.38%) | ||
| H.C. Wainwright Liver Disease Virtual Conference | 2025-10-21 07:00 | 10.45 (+2.40%) |
Show
Entries
Aligos Therapeutics Inc Frequently Asked Questions
What is Aligos Therapeutics Inc(ALGS)'s stock price today?
The current price of ALGS is $6.63. The 52 week high of ALGS is $13.69 and 52 week low is $4.80.
When is next earnings date of Aligos Therapeutics Inc(ALGS)?
The next earnings date of Aligos Therapeutics Inc(ALGS) is 2026-08-06 Est..
Does Aligos Therapeutics Inc(ALGS) pay dividends? If so, how much?
Aligos Therapeutics Inc(ALGS) does not pay dividend.
Guru Commentaries on NAS:ALGS
No articles.
Press Release
Articles on Aligos Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers